

## DAFTAR PUSTAKA

- Andreou, D., Werner, M., Pink, D., Traub, F., Schuler, M., Gosheger, G., Jobke, B., Reichardt, P., Tunn, P.U., 2015. Prognostic relevance of the mitotic count and the amount of viable tumour after neoadjuvant chemotherapy for primary, localised, high-grade soft tissue sarcoma. *Br. J. Cancer* 112: 455–460. doi:10.1038/bjc.2014.635
- Ballatori, S.E., Hinds, P.W., 2016. Osteosarcoma: prognosis plateau warrants retinoblastoma pathway targeted therapy. *Signal Transduct. Target. Ther.* 1: 16001. doi:10.1038/sigtrans.2016.1
- Baptista, A.M., Camargo, A.F.D.F., Filippi, R.Z., Oliveira, C.R.G.C.M.D., Azevedo Neto, R.S.D., Camargo, O.P.D., 2014. Correlation between the expression of vegf and survival in osteosarcoma. *Acta Ortopédica Bras.* 22: 250–255. doi:10.1590/1413-78522014220500978
- Becker, R.G., Galia, C.R., Morini, S., Viana, C.R., 2013. Immunohistochemical Expression of Vegf and Her-2 Proteins in Osteosarcoma Biopsies. *Acta Ortopédica Bras.* 21: 233–238. doi:10.1590/S1413-78522013000400010
- Benezech, S., Chabaud, S., Chambon, F., Dijoud, F., Chotel, F., Marec-Berard, P., 2016. Prognostic Value of Vascular Invasion in Pediatric Osteosarcomas. *Pathol. Oncol. Res.* 22: 847–852. doi:10.1007/s12253-016-0074-5
- Butters, O., Young, K., Cunningham, D., Chau, I., Starling, N., 2019. Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies. *Front. Oncol.* 9: 618. doi:10.3389/fonc.2019.00618
- Chui, M.H., Kandel, R.A., Wong, M., Griffin, A.M., Bell, R.S., Blackstein, M.E., Wunder, J.S., Dickson, B.C., 2016. Histopathologic Features of Prognostic Significance in High-Grade Osteosarcoma. *Arch. Pathol. Lab. Med.* 140: 1231–1242. doi:10.5858/arpa.2015-0389-OA
- Daft, P.G., Yang, Y., Napierala, D., Zayzafoon, M., 2015. The Growth and Aggressive Behavior of Human Osteosarcoma Is Regulated by a CaMKII-Controlled Autocrine VEGF Signaling Mechanism. *PLOS ONE* 10: e0121568. doi:10.1371/journal.pone.0121568
- Deok-Hoon Kong, Mi Kim, Ji Jang, Hee-Jun Na, Sukmook Lee, 2017. A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy. *Int. J. Mol. Sci.* 18: 1786. doi:10.3390/ijms18081786

- Ebeid, W., Amin, S., Abdelmegid, A., 2005. Limb salvage management of pathologic fractures of primary malignant bone tumors. *Cancer Control J. Moffitt Cancer Cent.* 12: 57–61. doi:10.1177/107327480501200107
- Fletcher, C.D., Bridge, J.A., Hogendoorn, P.C., Mertens, F., 2013. Osteogenic Tumours, in: WHO Classification of Tumours of Soft Tissue and Bone.
- Fletcher, C.D.M., World Health Organization, International Agency for Research on Cancer (Eds.), 2013. WHO classification of tumours of soft tissue and bone, 4th ed. ed, World Health Organization classification of tumours. IARC Press, Lyon.
- Goel, H.L., Mercurio, A.M., 2013. VEGF targets the tumour cell. *Nat Rev Cancer* 13: 871–882. doi:10.1038/nrc3627
- Hart, J., Zynger, D., 2019. Osteosarcoma [WWW Document]. URL <http://www.pathologyoutlines.com/topic/boneosteosarcomageneral.html> (accessed 2.10.20).
- Hide, geoff, Chew, F., 2018. Imaging in Classic Osteosarcoma [WWW Document]. URL <https://emedicine.medscape.com/article/393927-overview#a1> (accessed 2.10.20).
- Huang, H., Langenkamp, E., Georganaki, M., Loskog, A., Fuchs, P.F., Dieterich, L.C., Kreuger, J., Dimberg, A., 2015. VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF- $\kappa$ B-induced endothelial activation. *FASEB J.* 29: 227–238. doi:10.1096/fj.14-250985
- Kaya, M., Wada, T., Akatsuka, T., Kawaguchi, S., Nagoya, S., Shindoh, M., Higashino, F., Mezawa, F., Okada, F., Ishii, S., 2000. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* 6: 572–577.
- Lammler, J., Fan, M., Rosenthal, H.G., Patni, M., Rinehart, E., Vergara, G., Ablah, E., Wooley, P.H., Lucas, G., Yang, S.-Y., 2012. Expression of Vascular Endothelial Growth Factor correlates with the advance of clinical osteosarcoma. *Int. Orthop.* 36: 2307–2313. doi:10.1007/s00264-012-1629-z
- Lanitis, E., Irving, M., Coukos, G., 2015. Targeting the tumor vasculature to enhance T cell activity. *Curr. Opin. Immunol.* 33: 55–63. doi:10.1016/j.coi.2015.01.011
- Lee, J.A., 2015. Osteosarcoma in Korean children and adolescents. *Korean J. Pediatr.* 58: 123. doi:10.3345/kjp.2015.58.4.123
- Lewis, V.O., 2009. What's new in musculoskeletal oncology. *J. Bone Joint Surg. Am.* 91: 1546–1556. doi:10.2106/JBJS.I.00375

- Marko, T.A., Diessner, B.J., Spector, L.G., 2016. Prevalence of Metastasis at Diagnosis of Osteosarcoma: An International Comparison: Prevalence of Metastatic Osteosarcoma at Diagnosis. *Pediatr. Blood Cancer* 63: 1006–1011. doi:10.1002/pbc.25963
- Ottaviani, G., Jaffe, N., 2009. The Epidemiology of Osteosarcoma, in: Jaffe, N., Bruland, O.S., Bielack, S. (Eds.), *Pediatric and Adolescent Osteosarcoma*. Springer US, Boston, MA, pp. 3–13. doi:10.1007/978-1-4419-0284-9\_1
- Park, H.-R., Min, K., Kim, H.-S., Jung, W.W., Park, Y.-K., 2008. Expression of vascular endothelial growth factor-C and its receptor in osteosarcomas. *Pathol. - Res. Pract.* 204: 575–582. doi:10.1016/j.prp.2008.01.015
- Peng, N., Gao, S., Guo, X., Wang, G., Cheng, C., Li, M., Liu, K., 2016. Silencing of VEGF inhibits human osteosarcoma angiogenesis and promotes cell apoptosis via VEGF/PI3K/AKT signaling pathway. *Am. J. Transl. Res.* 8: 1005–1015.
- Putro, Y., 2017. Korelasi Ekspresi VEGF dan HER-2 dengan Profil Klinis, Parameter Laboratorium dan Tingkat Kelangsungan Hidup pada Pasien Osteosarkoma di RSUP Dr. Sardjito. Gadjah Mada University.
- Rastogi, S., Kumar, R., Sankineani, S.R., Marimuthu, K., Rijal, L., Prakash, S., Jalan, D., Khan, S.A., Sharma, M.C., 2012. Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: a prospective study. *Int. Orthop.* 36: 2315–2321. doi:10.1007/s00264-012-1663-x
- Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruner, G., Wienert, S., Van den Eynden, G., Baehner, F.L., Penault-Llorca, F., Perez, E.A., Thompson, E.A., Symmans, W.F., Richardson, A.L., Brock, J., Criscitiello, C., Bailey, H., Ignatiadis, M., Floris, G., Sparano, J., Kos, Z., Nielsen, T., Rimm, D.L., Allison, K.H., Reis-Filho, J.S., Loibl, S., Sotiriou, C., Viale, G., Badve, S., Adams, S., Willard-Gallo, K., Loi, S., 2015. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. *Ann. Oncol.* 26: 259–271. doi:10.1093/annonc/mdu450
- Seker, M.M., Seker, A., Aksoy, S., Ozdemir, N., Uncu, D., Zengin, N., 2014. Clinicopathologic Features and Prognosis of Osteosarcoma in Turkish Adults. *Asian Pac. J. Cancer Prev.* 15: 3537–3540. doi:10.7314/APJCP.2014.15.8.3537
- Shen, J.K., Cote, G.M., Choy, E., Yang, P., Harmon, D., Schwab, J., Nielsen, G.P., Chebib, I., Ferrone, S., Wang, X., Wang, Y., Mankin, H., Hornicek, F.J., Duan, Z., 2014. Programmed Cell Death Ligand 1 Expression in

- Osteosarcoma. *Cancer Immunol. Res.* 2: 690–698. doi:10.1158/2326-6066.CIR-13-0224
- Théoleyre, S., Mori, K., Cherrier, B., Passuti, N., Gouin, F., Rédini, F., Heymann, D., 2005. Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma. *BMC Cancer* 5: 123. doi:10.1186/1471-2407-5-123
- Wang, S., 2000. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. *J. Clin. Pathol.* 53: 374–381. doi:10.1136/jcp.53.5.374
- Wang, Z., Li, B., Ren, Y., Ye, Z., 2016. T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities. *Front. Immunol.* 7. doi:10.3389/fimmu.2016.00353
- Wei, S., Siegal, G.P., 2013. Atlas of bone pathology, Atlas of anatomic pathology. Springer, New York.
- Wu, H., Zhang, J., Dai, R., Xu, J., Feng, H., 2019. Transferrin receptor-1 and VEGF are prognostic factors for osteosarcoma. *J. Orthop. Surg.* 14: 296. doi:10.1186/s13018-019-1301-z
- Xie, L., Ji, T., Guo, W., 2017. Anti-angiogenesis target therapy for advanced osteosarcoma. *Oncol. Rep.* 38: 625–636. doi:10.3892/or.2017.5735
- Yu, X.-W., Wu, T.-Y., Yi, X., Ren, W.-P., Zhou, Z., Sun, Y., Zhang, C., 2014a. Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis. *Tumor Biol.* 35: 155–160. doi:10.1007/s13277-013-1019-1
- Yu, X.-W., Wu, T.-Y., Yi, X., Ren, W.-P., Zhou, Z., Sun, Y., Zhang, C., 2014b. Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis. *Tumor Biol.* 35: 155–160. doi:10.1007/s13277-013-1019-1
- Zhao, J., Zhang, Z.-R., Zhao, N., Ma, B.-A., Fan, Q.-Y., 2015. VEGF silencing inhibits human osteosarcoma angiogenesis and promotes cell apoptosis via PI3K/AKT signaling pathway 7.